<DOC>
	<DOCNO>NCT03046446</DOCNO>
	<brief_summary>This Open-label Study Assess Safety Repeat Dose FX006 Administered Patients Osteoarthritis Knee</brief_summary>
	<brief_title>Study Assess Safety Repeat Administration FX006 Administered Patients With Osteoarthritis Knee</brief_title>
	<detailed_description>This study open-label , repeat administration design 40 mg FX006 . The study conduct male female patient ≥ 40 year age symptomatic OA knee . Eligible patient offer participation receive initial IA injection FX006 administer index knee Day 1 . Patients receive initial injection FX006 return Weeks 4 8 evaluate 12 , 16 , 20 24 week repeat administration . At first evaluation patient determine meet repeat administration eligibility criterion , patient eligible receive second IA injection FX006 . Patients eligible receive second injection evaluate total 52 week post initial injection : Weeks 4 , 8 , 12 , 16 , 20 , 24 , 28 , 32 , 36 , 40 , 44 , 48 52 , regardless time receive second injection . In addition , X-rays complete Screening Week 52 assessment safety . Patients benefit initial treatment determine evaluation Week 12 complete study Week 12 follow-up visit . Patients eligible second injection FX006 evaluation Weeks 12 , 16 , 20 , 24 complete study Week 24 follow-up visit .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Written consent participate study Willingness ability comply study procedure visit schedule ability follow verbal write instruction Male female ≥ 40 year age Symptoms associate OA index knee ≥ 6 month prior Screening Currently meet ACR Criteria ( clinical radiological ) OA KellgrenLawrence ( KL ) Grade 2 , 3 4 index knee base Xray perform Screening Qualifying score WOMAC A Screening Day 1/Baseline Index knee pain &gt; 15 day last month ( report patient ) Body mass index ( BMI ) ≤ 40 kg/m2 Ambulatory good general health Willingness abstain use protocolrestricted medication study Reactive arthritis , rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis , arthritis associate inflammatory bowel disease History infection index knee joint Clinical sign symptom active knee infection crystal disease index knee within 1 month Screening Presence surgical hardware foreign body index knee Unstable index knee joint ( torn anterior cruciate ligament ) within 12 month Screening IA corticosteroid ( investigational market ) index knee within 3 month Screening IA hyaluronic acid ( investigational market ) index knee within 6 month Screening IV IM corticosteroid ( investigational market ) within 3 month Screening Oral corticosteroid ( investigational market ) within 1 month Screening Any IA drug/biologic use within 6 month Screening 5 halflives ( whichever longer ) ( e.g. , platelet rich plasma ( PRP ) injection , stem cell , prolotherapy amniotic fluid injection ) Prior administration FX006 Women childbearing potential use effective contraception pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Knee</keyword>
	<keyword>Pain</keyword>
	<keyword>Steroid</keyword>
	<keyword>Intra-articular</keyword>
	<keyword>Injection</keyword>
</DOC>